Apothecary By Design, a leading distributor of specialty pharmaceuticals and a BelHealth Investment Partners portfolio company, announced the acquisition of Village Fertility Pharmacy.
Headquartered in Waltham, Massachusetts, Village is a nationally recognized fertility-focused specialty pharmacy. For nearly 30 years, Village has been providing exceptional service, clinical support and educational resources to fertility patients and clinics nationwide. The Company has built outstanding relationships with some of the largest payors in New England as well as key manufacturers of fertility products. The combination of ABD and Village significantly expands and enhances the business to better support patients nationally in the $1 billion fertility pharmacy market.
Tom Madden, President of ABD, stated, “Village is a leader in fertility in the Northeast and has a respected reputation in the industry. Since partnering with BelHealth, the ABD executive team identified Village as the perfect partner to continue the expansion to become a national leader in the fertility marketplace.”
Richard Friedman, Executive Chairman of ABD and Operating Partner of BelHealth, added, “Village is an integral part of ABD’s strategy to become one of the nation’s leading fertility pharmacies. The Company has an outstanding reputation in their markets with both payors and providers.”
About Apothecary By Design
Founded in 2008 and headquartered in Portland, Maine, Apothecary By Design is a specialty pharmacy focused on Women’s Health, Infectious Diseases and Autoimmune Disorders. ABD services fertility patients nationally and other specialty patients throughout the Northeast. Apothecary by Design offers compassionate care to thousands of patients as well as clinical services and support to prescribers, payors and manufacturers.
About BelHealth Investment Partners
BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm typically invests $20-50 million per platform company across three core healthcare segments: Services, Products and Distribution. BelHealth is currently investing from Fund II, a $350 million fund.
